adaptive platform trial

April 27, 2021: COVID-19 Grand Rounds Continues With the ACTIV-6 Direct-to-Participant Platform Trial

Posted on by Damon Seils

PhotoIn this week’s COVID-19 Grand Rounds session, Dr. Susanna Naggie of Duke University and Dr. Elizabeth Shenkman of the University of Florida will present “ACTIV-6: A Direct-to-Participant Platform Trial of Repurposed Drugs for COVID-19 in Non-hospitalized Patients.” The Grand Rounds session will be held on Friday, April 30, at 1:00 pm eastern. Join the online meeting.

The NIH Collaboratory Coordinating Center is using its popular Grand Rounds platform to share late-breaking research and promote resources in support of clinical researchers affected by the COVID-19 public health emergency.

For previous COVID-19 Grand Rounds, and more news and resources related to the COVID-19 public health emergency, see the COVID-19 Resources page.

March 31, 2021: COVID-19 Grand Rounds Continues With the REMAP-CAP Global Adaptive Platform Trial

Posted on by Damon Seils

Dr. Derek AngusIn this week’s COVID-19 Grand Rounds session, Dr. Derek Angus of the University of Pittsburgh will present “Lessons From COVID-19: The First Year of the REMAP-CAP Global Adaptive Platform Trial.” The Grand Rounds session will be held on Friday, April 2, at 1:00 pm eastern. Join the online meeting.

The NIH Collaboratory Coordinating Center is using its popular Grand Rounds platform to share late-breaking research and promote resources in support of clinical researchers affected by the COVID-19 public health emergency.

For previous COVID-19 Grand Rounds, and more news and resources related to the COVID-19 public health emergency, see the COVID-19 Resources page.

August 21, 2020: Adaptive Platform Trials: Scalable from Breast Cancer to COVID (Laura Esserman, MD, MBA)

Posted on by Gina Uhlenbrauck

Speaker

Laura Esserman, MD, MBA
Director, UCSF Carol Franc Buck Breast Care Center
Alfred A. de Lorimier Endowed Chair in General Surgery
Professor of Surgery and Radiology, UCSF

Topic

Adaptive Platform Trials: Scalable from Breast Cancer to COVID

Keywords

COVID-19; Adaptive platform trial; Study design; Learning healthcare system; Collaborative research

Key Points

  • Adaptive trial design is an innovative, collaborative approach with the potential to maximize learning about treatments so as to prioritize therapeutic agents and drive better patient outcomes.
  • Adaptive platform trials are designed to identify early endpoints that can be captured in the course of care. Multiple agents are evaluated simultaneously, and those with a potential for big impact are advanced quickly.
  • As a “learning engine,” adaptive platform trials could be used to accelerate high-impact treatments for COVID-19 and future pandemics.

Discussion Themes

Essential to an adaptive platform trial are checklists of data and nimble EHR tools that evolve as the disease evolves.

What is the process to monitor for and make the decision to modify the standard of care backbone?

Read more about adaptive platform trials at the I-SPY Trials website and a recent Grand Rounds presentation, Optimized Learning While Doing: The REMAP-CAP Adaptive Platform Trial.

Tags

#pctGR, @Collaboratory1